A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
A phase 3 trial of Nadofaragene firadenovec, Gemcitabine, Docetaxel and Pembrolizumab in bladder & urothelial cancer, run by Ferring Pharmaceuticals, now recruiting.
Overview
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer is a phase 3 interventional study registered as NCT06545955 by Ferring Pharmaceuticals, with 250 participants planned, started 2024-10-01 and due to reach its primary completion in 2028-06-30. Interventions recorded: Nadofaragene Firadenovec, Gemcitabine, Docetaxel and Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialTrial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Shares Ferring Pharmaceuticals, Nadofaragene firadenovec, Bladder & urothelial cancer and the tag pipeline.
- TrialSafety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
Shares Ferring Pharmaceuticals, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
Shares Docetaxel, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Shares Docetaxel, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialModular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Shares Gemcitabine, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Shares Docetaxel, Bladder & urothelial cancer and the tag pipeline.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Shares Gemcitabine, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialStudy BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Shares Gemcitabine, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.